4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Cash from Investing Activities data on file, last reported at $68.9 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $68.9 million, up 115.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$56.0 million (down 674.9% YoY), and the FY2025 annual result was -$93.0 million, up 69.26% from the prior year.
• Cash from Investing Activities advanced to $68.9 million in Q1 2026 per FDMT's latest filing, from -$128.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $68.9 million in Q1 2026 and troughed at -$263.3 million in Q1 2024.
• A 5-year average of -$13.4 million and a median of $15.4 million in 2022 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 7897.56% in 2022 and fell as far as 8328.35% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at -$35.8 million in 2022, then surged by 81.32% to -$6.7 million in 2023, then soared by 205.64% to $7.1 million in 2024, then slumped by 1925.29% to -$128.8 million in 2025, then soared by 153.46% to $68.9 million in 2026.
• Business Quant data shows FDMT's Cash from Investing Activities at $68.9 million in Q1 2026, -$128.8 million in Q4 2025, and $17.8 million in Q3 2025.